Clinical Trial Update: Safety, Tolerability and Immunogenicity Induced by the THV01 Treatment in Patients Infected With HIV-1 Clade B and Treated With Highly Active Antiretroviral Therapy (HAART). [Phase 1, Phase 2]

View source ↗

Summary

Early-phase trial assessing safety, tolerability, and immunogenicity of THV01 in HIV-1 clade B–infected patients on HAART; completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• THV01

Snippet

Sponsor: Theravectys S.A. | Conditions: HIV Infection | Phase 1, Phase 2 | Status: COMPLETED